Last updated on June 2019

A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Brief description of study

The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary tumors.

Clinical Study Identifier: NCT02599324

Find a site near you

Start Over

Institut Catala d'Oncologia

Barcelona, Spain
  Connect »